Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study
| Autor: | Mercedes Codina, Juan Ramón Urgeles, Guillermo Serra, Iñaki Argüelles, Honorato García, Elena Mena, Santiago Tofé, Vicente Pereg |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Diabetes mellitus medicine Adverse effect Glucagon-like peptide 1 receptor business.industry Original Articles medicine.disease glycaemic control Tolerability GLP‐1 receptor agonist Observational study Original Article observational study business Body mass index |
| Zdroj: | Endocrinology, Diabetes & Metabolism |
| ISSN: | 2398-9238 |
| Popis: | Summary Aims To evaluate in a real‐world setting the effectiveness and tolerability of available GLP‐1 RA drugs in patients with type 2 diabetes after a prolonged follow‐up. Materials and methods Observational, retrospective, single‐centre study in patients starting GLP‐1 RA therapy. Change in HbA1c, fasting plasma glucose (FPG) and body mass index (BMI) along with gastrointestinal (GI) adverse events and withdrawal from GLP‐1 RA therapy were evaluated. Lack of efficacy of GLP‐1 RA therapy according to prespecified goals was also measured. Results A total of 735 patients were included, mean age 59.7 years, duration of diabetes 9.01 years, HbA1c 8.18% and BMI 38.56 kg/m2. Average follow‐up was 18.97 months (range 4.2‐39.09). All HbA1c (0.93%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text